Vor Biopharma Inc.

Drug developers and investors left San Francisco after the recent J.P. Morgan Healthcare Conference feeling optimistic about prospects for returns on biopharmaceutical investments, certain that forthc

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and

Broader stock market indices continue to swing wildly up and down as new data emerge showing that inflation is easing, but also that other parts of the economy continue to struggle. However, biotechno

Arbor Biotechnologies , Acrivon Therapeutics Inc. and bit.bio are the newest members of the biopharma venture capital mega-round club after the companies announced series B rounds totaling $215m, $100